secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-08-04T20:10:48+00:00
Accession:  0001178913-26-003796
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion: SIL204 shows multi-mechanism immune sensitization in KRAS-driven cancers
--------------------------------------------------------------------------------

- SIL204 treatment produced statistically significant upregulation of FAS (death receptor) and downregulation of HLA-G (immune checkpoint) in human KRAS-mutant pancreatic and NSCLC cell lines.
- Combined with prior MHC-I upregulation, data supports coordinated immune-sensitization across three key immune pathways.
- Findings observed across four distinct KRAS mutations (G12D, G12V, G12C, G12R) in pancreatic and NSCLC models.
- Company advancing SIL204 into Phase 2/3; first clinical trial site initiated at Tel Aviv Sourasky Medical Center in July 2026.
- Management believes data supports combining SIL204 with anti-PD-(L)1 checkpoint inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326003796/0001178913-26-003796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326003796/zk2635818.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-003796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer